Abstract: A high-voltage connector protective flap device for an electrical high-voltage connector, in particular a high-voltage charging connector for a vehicle having an electric traction motor or a charging station, having a holder, an actuator, and a protective flap, wherein the protective flap is configured to be pivotable between a closed position and an open position of the protective flap device on the holder to open and close a mating face of the high-voltage connector, and the protective flap device is designed such that the protective flap is pivotable as intended electromechanically by the actuator and furthermore the protective flap can alternatively be pivoted as intended manually.

Abstract: A dishwasher includes a wash container for items to be washed and configured to conduct at least water during operation, and a fluid line system having an inlet valve defined by a center line and configured for direct or indirect connection of a water inlet line from a water supply network. Disposed below the wash container is a base support having an outer wall provided with a cutout. The inlet valve is secured by a support part which is lockable in the cutout and has at least one externally open locking holder, into which the inlet valve is lockable and secured therein non-movably in an axial direction. The externally open locking holder is aligned in such a manner that the center line of an inlet of the inlet valve runs at an angle between >0° and <90° in relation to a lower face of the base support.

Abstract: The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.

Abstract: The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.

Abstract: A dishwasher includes a wash container for items to be washed and configured to conduct at least water during operation, and a fluid line system having an inlet valve defined by a center line and configured for direct or indirect connection of a water inlet line from a water supply network. Disposed below the wash container is a base support having an outer wall provided with a cutout. The inlet valve is secured by a support part which is lockable in the cutout and has at least one externally open locking holder, into which the inlet valve is lockable and secured therein non-movably in an axial direction. The externally open locking holder is aligned in such a manner that the center line of an inlet of the inlet valve runs at an angle between >0° and <90° in relation to a lower face of the base support.

Abstract: The invention is directed to formulations of lipophilic Amyloid ?eta ligand stilbene based derivatives and more particularly to formulations which are administrable parentally e.g. intravenously wherein the lipophilic Amyloid ?eta ligand stilbene based derivative is a 19F or 18F-labeled radiopharmaceutical thereof. Further, the invention is directed to a method for sterile filtration of said suitable formulation.

Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 ?, 5.14 ?, 4.84 ?, 4.55 ?, 4.34 ?, 4.07 ?, 3.51 ?, 3.48 ?, 3.25 ?, 3.19 ?, 3.15 ?, 3.07 ?, and 2.81 ?, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Abstract: An apparatus (2) for treating a cooling and rinsing fluid stemming from a soiled drilling fluid (15), including a first container (20) that collects the soiled drilling fluid (15), a second container (21) that is connected to a discharge line (38) for the treated cooling and rinsing fluid (36), a pressure switch (41) that is arranged in the discharge line (38) for purposes of measuring the pressure, and a control unit (40) for switching the treatment apparatus (2) over between a first mode of operation and at least one other mode of operation, whereby the treatment apparatus (2) can be switched over between the first and the at least one other mode of operation as a function of the pressure measured in the discharge line (38).

Abstract: A device for processing a cooling and flushing liquid from a dirty liquid is disclosed. The device includes a first container, which cooperates with a suction device for the dirty liquid and collects the suctioned dirty liquid, a second container, which cooperates with an overpressure device, and a filter element, which is arranged in the second container. The filter element is arranged in a direction of flow before the second container.

Abstract: A device and method for processing a cooling and rinsing liquid from a dirty liquid is disclosed. The device includes a first container, which is connected to a feed line for the dirty liquid, a second container, which is connected to a discharge line for the process cooling and rinsing liquid, and a filter element which is arranged in the second container. A connecting line connects the first and second containers and a bypass line connects the discharge line to the connecting line.

Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 ?, 5.14 ?, 4.84 ?, 4.55 ?, 4.34 ?, 4.07 ?, 3.51 ?, 3.48 ?, 3.25 ?, 3.19 ?, 3.15 ?, 3.07 ?, and 2.81 ?, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Abstract: Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Abstract: Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Abstract: A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

Abstract: An improved process for the preparation of sertraline hydrochloride polymorphic form II is described, which process comprises seeding a solution of sertraline free amine in a ketone with some crystals of polymorphic form II and addition of hydrogen chloride, and wherein the solution is heated before addition of the hydrogen chloride. According to the present process, the metastable form II may be obtained in a reliable way with good yield and high purity with respect to other polymorphic forms as well as preparative residues such as educts or solvents.

Abstract: A cystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

Abstract: Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomers of fluvastatin, referred to as polymorphic Forms A, B1, B2, C, D and E, processes for the preparation of these crystalline forms and pharmaceutical compositions comprising them are disclosed.

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1